← Leaderboards
David S Schade
University Of New Mexico
$14,177,133
Attributed
$16,819,752
Total exposure
42
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$16,819,752 · 42
By mechanism
U01$8,464,374 · 1
M01$3,070,140 · 39
R44$2,927,687 · 1
DP3$2,357,551 · 1
Top collaborators
- Peter N Soliz3 shared
- Rose A Gubitosi-Klug1 shared
Most similar at University Of New Mexico
Same institution · by research overlap
- Mark R Burge$7,348,770
- Melvina L McCabe$0
- R P Eaton$3,609,690
- Sally C Seidel$1,553,955
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusClinical ResearchHuman SubjectFundingCohortMetforminFollow-UpDiabetes Mellitus TherapyCardiovascular Disorder RiskGrantBasePreventInsulin Dependent Diabetes MellitusDisease /Disorder Prevention /ControlEpidemiologyClinical TrialsDiabetes PreventionAtherosclerosisCardiovascular DiseasesPlacebosDiabetes Prevention ProgramLifestyle InterventionAffectIncidence
Grant awards (91)
Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy.$955,879
R44 · FY2022 · DK
Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy.$982,699
R44 · FY2021 · DK
19/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study-Clinical Center$1
U01 · FY2021 · DK · contact PI
Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy.$989,109
R44 · FY2020 · DK
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$263,486
U01 · FY2020 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$313,764
U01 · FY2019 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$259,900
U01 · FY2018 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$270,947
U01 · FY2017 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$262,584
U01 · FY2016 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$43,935
U01 · FY2016 · DK · contact PI
19/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project$27,947
U01 · FY2016 · DK · contact PI
DPPOS Follow-up$232,897
U01 · FY2015 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$386,015
U01 · FY2014 · DK · contact PI
Hearing Impairment in Long-Term Type 1 Diabetes$2,357,551
DP3 · FY2013 · DK
Diabetes Prevention Program Outcomes Study - Phase 2$544,797
U01 · FY2013 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$566,716
U01 · FY2012 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$543,485
U01 · FY2011 · DK · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$525,245
U01 · FY2010 · DK · contact PI
THE IMPORTANCE OF INSULIN TIMING IN TYPE 1 DIABETES$32,880
M01 · FY2010 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$5,353
M01 · FY2010 · RR · contact PI
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$5,098
M01 · FY2010 · RR · contact PI
Diabetes Prevention Program Outcomes Study - Phase 2$523,500
U01 · FY2009 · DK · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$18,580
M01 · FY2009 · RR · contact PI
POSTPRANDIAL HYPERGLYCEMIA$18,580
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$16,516
M01 · FY2009 · RR · contact PI
Post DPP Follow-up Study$399,369
U01 · FY2008 · DK · contact PI
CLINICAL TRIAL: EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$14,537
M01 · FY2008 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$14,053
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: VITAMIN THERAPY IN TYPE-2 DIABETES (PATHOGENESIS OF ATHEROSCLERO$8,722
M01 · FY2008 · RR · contact PI
POSTPRANDIAL HYPERGLYCEMIA$4,845
M01 · FY2008 · RR · contact PI
Post DPP Follow-up Study$201,470
U01 · FY2007 · DK · contact PI
VITAMIN THERAPY IN TYPE-2 DIABETES (PATHOGENESIS OF ATHEROSCLEROSIS)$50,005
M01 · FY2007 · RR · contact PI
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$15,889
M01 · FY2007 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$8,879
M01 · FY2007 · RR · contact PI
VITAMINS AND DIET IN TYPE 2 DIABETES$2,804
M01 · FY2007 · RR · contact PI
DIABETES PREVENTION PROGRAM OUTCOME STUDY (DPPOS)$1,402
M01 · FY2007 · RR · contact PI
Post DPP Follow-up Study$305,347
U01 · FY2006 · DK · contact PI
VITAMIN THERAPY IN TYPE-2 DIABETES (PATHOGENESIS OF ATHEROSCLEROSIS)$78,399
M01 · FY2006 · RR · contact PI
THE ADVANTAGES OF GLIPIZIDE XL IN THE POSTPRANDIAL PERIOD$66,339
M01 · FY2006 · RR · contact PI
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$19,021
M01 · FY2006 · RR · contact PI
EFFECT OF TWO DAY BED REST ON METABOLIC STATUS AND CARDIOVASCULAR RISK FACTORS$9,279
M01 · FY2006 · RR · contact PI
DIABETES PREVENTION PROGRAM OUTCOME STUDY (DPPOS)$8,350
M01 · FY2006 · RR · contact PI
VITAMINS AND DIET IN TYPE 2 DIABETES$3,712
M01 · FY2006 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$1,392
M01 · FY2006 · RR · contact PI
Post DPP Follow-up Study$205,197
U01 · FY2005 · DK
EFFECT OF TWO DAY BED REST ON METABOLIC STATUS AND CARDIOVASCULAR RISK FACTORS$120,805
M01 · FY2005 · RR
THE ADVANTAGES OF GLIPIZIDE XL IN THE POSTPRANDIAL PERIOD$33,959
M01 · FY2005 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$31,732
M01 · FY2005 · RR
VITAMIN THERAPY IN TYPE-2 DIABETES (PATHOGENESIS OF ATHEROSCLEROSIS)$21,155
M01 · FY2005 · RR
PHYSIOLOGICAL RESPONSE TO MEALS IN NON-INSULIN-DEPENDENT DIABETES$19,485
M01 · FY2005 · RR
DIABETES PREVENTION PROGRAM OUTCOME STUDY (DPPOS)$12,247
M01 · FY2005 · RR
DIABETES PREVENTION PROGRAM$556
M01 · FY2005 · RR
Post DPP Follow-up Study$301,779
U01 · FY2004 · DK
Effect of Two Day Bedrest on Metabolic Status$38,548
M01 · FY2004 · RR
Epidemiology of Diabetes Intervention and Complications (EDIC)$28,492
M01 · FY2004 · RR
Diabetes Prevention Program Outcome Study (DPPOS)$5,586
M01 · FY2004 · RR
Diabetes Prevention Program$1,676
M01 · FY2004 · RR
Response to Meals in Non-Insulin-Dependent Diabetes$1,118
M01 · FY2004 · RR
Diabetes Prevention Trial of Type I Diabetes (DPT-1)$1,118
M01 · FY2004 · RR
Post DPP Follow-up Study$395,573
U01 · FY2003 · DK
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$282,412
M01 · FY2002 · RR
ADRENAL GLAND AND DIABETES$282,412
M01 · FY2002 · RR
DIABETES PREVENTION PROGRAM$282,412
M01 · FY2002 · RR
DIABETES PREVENTION TRIAL OF TYPE I DIABETES (DPT-1)$282,412
M01 · FY2002 · RR
PRIMARY PREVENTION TRIAL (DPT-2)$250,000
U01 · FY2002 · DK
GLUCOSE HOMEOSTASIS IN TYPE I AND BRITTLE TYPE I DIABETES$0
M01 · FY2002 · RR
SMOKING AND DIABETES$0
M01 · FY2002 · RR
PATHOGENESIS OF BRITTLE DIABETES$0
M01 · FY2002 · RR
PRIMARY PREVENTION TRIAL (DPT-2)$885,811
U01 · FY2001 · DK
DIABETES PREVENTION TRIAL OF TYPE I DIABETES (DPT-1)$282,412
M01 · FY2001 · RR
ADRENAL GLAND AND DIABETES$282,412
M01 · FY2001 · RR
DIABETES PREVENTION PROGRAM$282,412
M01 · FY2001 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$282,412
M01 · FY2001 · RR
SMOKING AND DIABETES$0
M01 · FY2001 · RR
PATHOGENESIS OF BRITTLE DIABETES$0
M01 · FY2001 · RR
GLUCOSE HOMEOSTASIS IN TYPE I AND BRITTLE TYPE I DIABETES$0
M01 · FY2001 · RR
PRIMARY PREVENTION TRIAL (DPT-2)$754,609
U01 · FY2000 · DK
DIABETES PREVENTION TRIAL OF TYPE I DIABETES (DPT-1)$22,433
M01 · FY2000 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$22,433
M01 · FY2000 · RR
ADRENAL GLAND AND DIABETES$22,433
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM$22,433
M01 · FY2000 · RR
PATHOGENESIS OF BRITTLE DIABETES$0
M01 · FY2000 · RR
GLUCOSE HOMEOSTASIS IN TYPE I AND BRITTLE TYPE I DIABETES$0
M01 · FY2000 · RR
GLUCOSE HOMEOSTASIS IN TYPE I AND BRITTLE TYPE I DIABETES$0
M01 · FY2000 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)$0
M01 · FY2000 · RR
ADRENAL GLAND AND DIABETES$0
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL OF TYPE I DIABETES (DPT-1)$0
M01 · FY2000 · RR
DIABETES PREVENTION PROGRAM$0
M01 · FY2000 · RR
SMOKING AND DIABETES$0
M01 · FY2000 · RR
SMOKING AND DIABETES$0
M01 · FY2000 · RR
PATHOGENESIS OF BRITTLE DIABETES$0
M01 · FY2000 · RR